Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1363 - RAS (Kirsten RAS and Neuroblastoma RAS) mutation testing for eligibility for panitumumab treatment in previously untreated metastatic colorectal cancer patients

Application Number

1363
Application NameRAS (Kirsten RAS and Neuroblastoma RAS) mutation testing for eligibility for panitumumab treatment in previously untreated metastatic colorectal cancer patients.
Description of Medical ServiceThe RAS mutation test is a combination of genetic tests, conducted on a biopsy sample, to tell whether a tumour carries a RAS mutation(s). KRAS and NRAS are highly related members of the RAS oncogene family which have an important role in the development and continued growth of colorectal cancer. The KRAS gene is found to be mutated, or changed, in about 40% of people with colorectal cancer. The NRAS gene is found to be mutated in an additional 10-15% of patients. The other ~50% of people have a non-mutated (sometimes called “wild type”) RAS genes.
Description of Medical ConditionWidespread colorectal cancer is treated with chemotherapy and patients may receive several sequential courses of different types of chemotherapy as the disease progresses. For patients with widespread disease the prognosis is poor with only 10% of patients still alive 5 years after diagnosis.
Consultation ProtocolNot required
Final ProtocolNot required
Reports-
MSAC OutcomesPublic Summary Document (PDF 181 KB)
Public Summary Document (Word 158 KB)

Meetings for this Application

Meeting Type:Date:
PASCNot required
ESC 12 and 13 June 2014
MSAC 3 October 2014

Page currency, Latest update: 16 April, 2015